Skip to content
← Back to ingredients

Baricitinib

Also known as: Olumiant

Strong EvidencePharmaceuticalAlopecia Areata

FDA-approved oral JAK1/JAK2 inhibitor for severe alopecia areata in adults.

Regrowth Potential60%
Long-Term Viability75%

Mechanism of Action

Baricitinib selectively inhibits Janus kinase 1 (JAK1) and JAK2, blocking the JAK-STAT signaling pathway that drives the autoimmune T-cell attack on hair follicles in alopecia areata. By suppressing interferon-gamma and interleukin-15 signaling, it restores immune privilege of the hair follicle.

Unlock Premium Content

Get full access to in-depth analyses, cited studies, premium articles, and AI chat.

$12/mo

View pricing